Liu J, Kosma V-M, Vnttinen T, Hydn-Granskog C, Voutilainen R
The benefits of GLP-1 receptor agonists for type 2 diabetes, obesity, and cardiovascular disease are established, but their impact on chronic kidney disease has been less certain
Circanas report suggested additional considerations for companies impacted by GLP-1 use
It is estimated that approximately 1 in 4 people in the world have NAFLD
We can also support the bodys ability to make glutathione through supplements like N-acetylcysteine (NAC), glycine, glutamate, and selenium
Both tirzepatide and GLP-1 therapies have demonstrated strong benefits for: Weight management Blood sugar control Metabolic improvement Tirzepatide may offer enhanced results for some individuals due to its dual hormone targeting, but the choice depends on medical history, goals, and tolerability